Suven Life Sciences Limited — Others, 03-02-2025: Monitoring Agency Report

Suven Life Sciences Limited has submitted the Monitoring Agency report confirming the appropriate utilization of proceeds from its Rights Issue for the quarter ending December 31, 2024. The report, prepared by CRISIL Ratings Limited, indicates no deviations from planned expenditures. The company utilized ₹33,220.48 crore of the ₹39,700.18 crore raised, focusing on pharmaceutical R&D and inter-corporate deposits. This transparency could enhance investor confidence, indicating robust financial management and a positive outlook for future endeavors in the competitive pharmaceutical sector.